本项目拟在前期GWAS工作基础上，利用imputation和Meta分析方法，深度分析和挖掘GWAS数据，寻找新的IgA肾病易感基因。具体步骤包括：1）扩大GWAS一期研究样本量，以“千人基因组计划”数据为参考，对IgA肾病GWAS数据进行imputation分析，发现差异表达SNPs，并在大样本人群中进行验证，从而发现更多IgA肾病易感基因；2）联合国外IgA肾病研究团队，获得数个独立种族人群IgA肾病GWAS数据，利用Meta分析方法，整合并对多个GWAS数据进一步分析，以期发现IgA肾病新的易感基因，同时对易感基因在不同种族人群中的数据进行分析，以期发现IgA肾病发病机制的遗传异质性；3）将易感基因与IgA肾病患者的临床表现、病理类型、预后和治疗反应进行相关性分析，以发现早期预测IgA肾病临床结局和治疗反应的易感基因，为探讨早期预警IgA肾病的生物学标记，指导个体化治疗提供基础。

On the basis of our previous GWAS, we use imputation and Meta analysis to conduct an in-depth analysis of the GWAS data, to identify the new susceptibility genes for IgA nephropathy (IgAN). This includes the following steps: 1) expanding the sample size of the discovery stage of GWAS, using “1000 genomes project” as the reference panel, doing the imputation analysis of the GWAS data for IgAN, selecting the significant SNPs and validating in a large separate cohort, to identify more novel susceptibility genes for IgAN. 2) Collaborating with the foreign research team for IgAN, obtaining the GWAS data of several different ethnic populations, using Meta analysis to identify the new susceptibility genes for IgAN, and investigating the genetic heterogeneity in the pathogenesis of IgAN by analyzing the data of different ethnic groups. 3) studying the correlation of the susceptibility genes and the clinical manifestation, pathological pattern, prognosis and response to treatment of IgAN patients, to detect the susceptibility genes for early prediction of the clinical outcomes and response to treatment, to explore the biological markers of early warning for IgAN and guide the individualized treatment.